RFK Promised 14 Peptides Back. Two Weeks Later, Here's What Changed.

What Kennedy Actually Said

Let's start with what we know, directly from the source.

On Episode #2461 of the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. made three specific claims about peptides:

**One.** He personally uses them. "I'm a big fan of peptides," he told Rogan. Not "peptides show promise." Not "we're studying the issue." The man who oversees the FDA said he uses the compounds his own agency banned.

**Two.** Approximately 14 of the 19 compounds the FDA placed on its Category 2 restricted list will be moved back to Category 1.

**Three.** He characterized the original Category 2 placements as illegal, arguing the FDA lacked legitimate safety signals to justify the ban.

> "My hope is that they're going to get moved to a place where people have access from ethical suppliers."

Those five words, "access from ethical suppliers," matter more than any of the policy language. They signal a philosophical shift at the top of HHS. Kennedy views the compounding ban not as consumer protection, but as a barrier that pushed patients toward the unregulated grey market.

The same grey market that collapsed a week later.

On March 6, 2026, Peptide Sciences, the largest research peptide vendor in the United States, voluntarily shut down. Seven days after Kennedy's announcement. Coincidence or calculated exit? Either way, the timing is hard to ignore.

We covered the RFK announcement in detail the day it aired. For the full breakdown of what he said and why it matters, read our same-day analysis.

This article is about what happened next. Or more precisely: what hasn't.

How 19 Compounds Disappeared Overnight

To understand the Category 1 shift, you need to understand the Category 2 ban that preceded it.

On September 29, 2023, the FDA updated its interim 503A Bulk Drug Substances list and placed 19 compounds into Category 2. In regulatory language, Category 2 means the FDA has identified "significant safety risks." In practical language, it means a flat ban on compounding. No prescriptions filled. No patient access through licensed pharmacies. Effective immediately.

Nineteen compounds. Gone from legal compounding channels in a single list update.

Here's what the FDA did not do before making that change:

• It did not consult the Pharmacy Compounding Advisory Committee, its own expert panel.
• It did not open a public comment period.
• It did not publish a Federal Register notice inviting input from pharmacies, physicians, or patients.
• It did not cite specific adverse event data for the majority of the compounds.

It simply updated a web page.

That lack of process is what Kennedy called "illegal." It's also what a federal lawsuit would later call a violation of the Administrative Procedure Act. More on that in a moment.

For a deeper dive into the full regulatory framework, including how 503A and 503B pharmacies differ and what each designation actually means, we've written a comprehensive guide to FDA peptide regulations.

The Full 19

Here is every compound the FDA placed on Category 2 of its 503A bulks list on September 29, 2023. We've included the common therapeutic context for each, along with the expected status based on Kennedy's announcement and regulatory analyst commentary.

**Important:** The "Expected Status" column reflects analyst speculation based on Kennedy's public statements and known safety profiles. The FDA has not published an official revised list. Nothing in this table should be taken as confirmed regulatory action.

_Ibutamoren Mesylate is technically a small molecule, not a peptide. It was included on the 503A bulks list alongside the 18 peptide compounds._

Of the 19, Kennedy indicated approximately 14 will return to Category 1. The five that stay restricted have not been officially identified. Regulatory analysts most commonly cite **Melanotan II** (cardiovascular effects, theoretical melanoma risk from melanocyte stimulation) and **Cathelicidin LL-37** (minimal human clinical data) as the most likely to remain. **Dihexa Acetate** (extremely potent, limited safety profile), **Emideltide** (few published human studies), and **Ibutamoren Mesylate** (cortisol and prolactin elevation concerns; voted down by PCAC in October 2024) round out the speculated five.

But speculation is all it is until the FDA publishes the list.

The Legal Fight That Made This Possible

The Category 2 ban didn't go unchallenged.

On March 29, 2024, Evexias Medical Centers, Evexias Health Solutions, and FarmaKeio Pharmacy filed suit against the FDA in the United States District Court for the Northern District of Texas. Case No. 4:24-cv-00293. The core argument: the FDA violated the Administrative Procedure Act by placing compounds on Category 2 without following its own required process. No PCAC consultation. No public notice. No opportunity for comment from the pharmacies, physicians, and patients who relied on these compounds.

The lawsuit resulted in a settlement in September 2024. The terms forced the FDA to do what it should have done from the beginning: submit the peptides to its Pharmacy Compounding Advisory Committee for formal review in public meetings.

Two meetings were scheduled. What happened at those meetings is the part of this story most people don't know.

**October 29, 2024.** The PCAC reviewed four substances nominated for inclusion on the 503A bulks list: L-theanine, ibutamoren mesylate, ipamorelin, and kisspeptin-10. The committee voted against all four.

**December 4, 2024.** The PCAC reviewed three more: AOD-9604 (and related salt forms), CJC-1295 (and variants including DAC), and thymosin alpha-1 (acetate and free base). FDA staff recommended against inclusion. The committee voted against all three.

Seven substances reviewed across two public meetings. Seven rejections. Zero approvals.

Let that sit for a moment.

The expert advisory committee that the HHS Secretary's own department oversees reviewed these peptides through the proper regulatory channel: evidence submissions, public testimony, scientific deliberation. The committee rejected every single one.

Now the same department's political appointee says he's bringing them back anyway.

Whether you see that as correcting an original injustice (the September 2023 ban that skipped this very process) or overriding scientific expertise (the committee's unanimous rejections) depends entirely on where you stand. Reasonable people disagree.

But here's what isn't debatable: an announcement on a podcast is not the same thing as a published regulatory action. And as of March 12, 2026, only one of those things has happened.

What Category 1 Actually Means

Before we go further, let's translate the regulatory language.

**Category 1** on the FDA's 503A bulks list means this: the substance has been evaluated, and the FDA does not intend to take enforcement action against a compounding pharmacy that uses it. In practice, a licensed 503A pharmacy can legally prepare the compound for a patient who has a valid prescription from a licensed physician.

That's it. That's all Category 1 means.

What Category 1 does **not** mean:

• **Not FDA-approved.** These are not approved drugs. No approved indication, no standardized dosing, no official package insert.
• **Not over the counter.** You need a prescription from a licensed physician.
• **Not available from just any pharmacy.** Only licensed compounding pharmacies under Section 503A or 503B of the FD&C Act.
• **Not covered by insurance.** Compounded peptides are out-of-pocket. Typical range: $100 to $400 per month depending on compound and pharmacy.
• **Not instant.** Even after formal reclassification, pharmacies need to source raw materials, establish quality testing protocols, and restart production. That takes weeks to months.

Category 1 is _permission_, not _endorsement_. It means the FDA won't come after your pharmacy for compounding BPC-157. It does not mean the FDA considers BPC-157 proven for any specific condition.

The distinction matters. It's the difference between "legal" and "proven." Both are useful. Neither should be confused for the other.

The Gap Between Promise and Access

Here's the uncomfortable reality facing peptide patients in March 2026.

The grey market is collapsing. Peptide Sciences shut down on March 6. They weren't the first vendor to close, but they were the biggest: an estimated quarter-billion-dollar operation running out of a virtual mailbox in Henderson, Nevada. They read the regulatory tea leaves and closed the laptop rather than fight the FDA.

Meanwhile, the legal channel has not been officially reopened. The Category 1 reclassification that would restore compounding pharmacy authority to prepare these peptides has been announced but not published. A podcast appearance is not a Federal Register notice. And compounding pharmacies that follow the law won't restart production based on a Joe Rogan clip.

So where does a patient with a valid prescription go today?

**Option 1: A compounding pharmacy that continued operations.** Some pharmacies have continued compounding certain Category 2 peptides, accepting the legal risk. The quality at PCAB-accredited facilities is likely the highest available. Ask your physician or contact pharmacies directly.

**Option 2: A research peptide vendor.** Vendors selling compounds labeled "for research use only" still exist. Quality varies enormously. If you go this route, learn to read a certificate of analysis and understand what separates a credible vendor from a dangerous one.

**Option 3: Wait.** If the formal reclassification happens on Kennedy's timeline, licensed pharmacies could have these compounds available within weeks of publication.

None of these options is ideal. That's the gap. The promise was made at the speed of a podcast. The regulatory machinery moves at the speed of the Federal Register.

What Actually Changes When It Happens

When the FDA formally publishes the Category 1 reclassification (and at this point, the political will appears to be there) here's what changes practically.

For patients

• You will need a prescription from a licensed physician. No exceptions.
• You will fill that prescription at a licensed 503A or 503B compounding pharmacy. Our directory lists 827+ verified providers, including compounding pharmacies.
• Pricing: expect $100 to $400 per month, depending on compound, dosage, and pharmacy. BPC-157 may land on the lower end. Growth hormone secretagogues like CJC-1295/Ipamorelin typically run higher.
• Insurance will not cover compounded peptides. This is cash-pay medicine.
• Quality will be higher than grey market alternatives. Licensed pharmacies operate under USP compounding standards (503A) or pharmaceutical cGMP (503B).

For compounding pharmacies

• Category 1 is enforcement discretion, not permanent approval. It could be reversed again by a future administration.
• Raw material supply chains will need time to scale. Peptide synthesis requires specialized manufacturers.
• Expect a demand surge the moment the formal announcement lands.

For the grey market

• The "research chemical" loophole remains legally ambiguous. Vendors selling peptides "for research purposes only" are not directly affected by the 503A/503B framework.
• But Kennedy's language points clearly toward licensed pharmacies, not unregulated online vendors. "Ethical suppliers" was the phrase he used.
• Enforcement pressure on grey market vendors is likely to continue. The Peptide Sciences shutdown may be the beginning of a wave, not an isolated event.

What We Don't Know

Honest accounting of the gaps in this story. There are more unknowns than most coverage admits.

**When will the formal reclassification be published?** Kennedy said "within weeks" on February 27. It's been two weeks, and nothing has appeared in the Federal Register. The court filing in _Evexias v. FDA_ references a final rule deadline of no later than March 14, 2027. That's a 12-month window, not a two-week one.

**Which five compounds stay in Category 2?** Not confirmed. The speculation in this article is informed by regulatory analyst commentary and known safety profiles. The FDA has not published the split.

**Will the PCAC be consulted again?** The advisory committee voted against every peptide it reviewed in late 2024. If political leadership overrides those recommendations without reconvening the panel, it sets a precedent. The committee's role in future compounding decisions is an open question.

**What happens to pharmacies that jump the gun?** Some compounding pharmacies may restart operations based on Kennedy's public statements alone, before formal publication. The legal risk is real. A podcast interview, even from the HHS Secretary, does not change the regulatory status of a substance on the FDA's official list.

**How will this interact with the semaglutide compounding fight?** The Category 2 issue is separate from the GLP-1 compounding crisis ( semaglutide, tirzepatide). Those are FDA-approved drugs with shortage-dependent compounding rules. But the broader signal, that this administration favors expanded compounding access, applies to both situations.

**What about peptide pricing?** More legal supply typically means more competition and lower prices. But compounding pharmacies have real overhead: quality testing, compliance, pharmacy staff. Compounded peptides will cost more than grey market research chemicals. They'll also be safer.

**Will genetic testing matter for peptide selection?** As compounding access expands, the question shifts from "can I get this peptide?" to "which peptide is right for me?" Pharmacogenomic testing can help answer that, especially for compounds that interact with specific metabolic pathways.

The Bottom Line

Fourteen compounds. Two weeks of silence. A promise made on the world's biggest podcast. A regulatory machine that runs on its own clock.

The Category 1 shift, when it happens, will be the most significant expansion of legal peptide access in the United States since the FDA created the bulk drug substance categories. It will not make these compounds FDA-approved. It will not make them covered by insurance. It will not tell you which one is right for your specific condition.

What it will do is give licensed pharmacies the legal authority to compound them again. And it will give patients with valid prescriptions a path to access that doesn't run through the grey market, the same grey market that is rapidly disappearing.

The promise has been made. The paperwork has not.

In regulatory terms, only one of those things counts.

_We'll update this article the moment the formal reclassification is published._

:::cta **Looking for a licensed peptide provider?** Our directory lists 827+ verified providers, including compounding pharmacies that can fill your prescription once the reclassification is formalized.

Browse the Provider Directory :::